Allan Gibofsky
#153,995
Most Influential Person Now
Researcher
Allan Gibofsky's AcademicInfluence.com Rankings
Allan Gibofskyphilosophy Degrees
Philosophy
#8638
World Rank
#12052
Historical Rank
Logic
#5663
World Rank
#7080
Historical Rank
Allan Gibofskybiology Degrees
Biology
#11723
World Rank
#15144
Historical Rank
Immunology
#766
World Rank
#789
Historical Rank
Download Badge
Philosophy Biology
Allan Gibofsky's Degrees
- Doctorate Medicine Columbia University
Why Is Allan Gibofsky Influential?
(Suggest an Edit or Addition)Allan Gibofsky's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- American College of Rheumatology. (2002) (2985)
- Treating rheumatoid arthritis to target: recommendations of an international task force (2010) (1927)
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force (2015) (1155)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 (2006) (464)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 (2011) (464)
- Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. (2012) (416)
- Social support as a double-edged sword: the relation of positive and problematic support to depression among rheumatoid arthritis patients. (1991) (416)
- Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization (1980) (315)
- Chronic Lyme arthritis. Clinical and immunogenetic differentiation from rheumatoid arthritis. (1979) (240)
- Disease associations of the Ia-like human alloantigens. Contrasting patterns in rheumatoid arthritis and systemic lupus erythematosus (1978) (183)
- Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis (2004) (183)
- Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis. (2014) (180)
- Presence of a non-HLA B cell antigen in rheumatic fever patients and their families as defined by a monoclonal antibody. (1989) (168)
- Association of a B-cell alloantigen with susceptibility to rheumatic fever (1979) (155)
- A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry (2012) (154)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 (2013) (145)
- Expression of Ia-like antigens on cultured human malignant melanoma cell lines. (1978) (131)
- Assessing the impact of self-efficacy beliefs on adaptation to rheumatoid arthritis. (1991) (121)
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (2012) (120)
- Special characteristics of cellular immune function in normal individuals of the HLA-DR3 type. (1982) (105)
- Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. (2002) (103)
- Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. (1984) (102)
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement (2012) (101)
- A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. (2017) (93)
- Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire (2011) (93)
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003) (2003) (91)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 (2009) (87)
- Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry (2011) (84)
- Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry (2006) (79)
- Defective Fc receptor-mediated function of the mononuclear phagocyte system in lupus nephritis. (1982) (76)
- Familial systemic lupus erythematosus in males. (1983) (72)
- The genetics of rheumatic fever: relationship to streptococcal infection and autoimmune disease. (1991) (70)
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 (2008) (70)
- Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. (2003) (69)
- Silicone gel filled breast implants and connective tissue disease: an overview. (1994) (68)
- Cross-reactivity between streptococcus and human tissue: a model of molecular mimicry and autoimmunity. (1989) (65)
- Neonatal lupus erythematosus with heart block: family study of a patient with anti-SS-A and SS-B antibodies. (1983) (56)
- Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database. (2011) (56)
- Association of HLA-DRw2 with autoimmune thrombocytopenic purpura. (1979) (53)
- Medium effects for single ions in acetonitrile and ethanol-water solvents based on reference-electrolyte assumption. (1972) (51)
- Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial (2020) (50)
- Contrasting patterns of newer histocompatibility determinants in patients with rheumatoid arthritis and systemic lupus erythematosus. (1978) (50)
- Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study (2006) (49)
- Need to develop new nonsteroidal anti-inflammatory drug formulations. (2012) (48)
- Rheumatic fever. The relationships between host, microbe, and genetics. (1998) (47)
- Immunogenetic and clinical findings in idiopathic pulmonary fibrosis. Association with the B-cell alloantigen HLA-DR2. (2015) (42)
- Musculoskeletal manifestations of thyroid disease. (2010) (39)
- Impaired fc-mediated mononuclear phagocyte system clearance in HLA-DR2 and MT1-positive healthy young adults (1983) (38)
- Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? (2011) (38)
- Sex differences in gout characteristics: tailoring care for women and men (2017) (37)
- Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. (2000) (36)
- A Phase 2b Randomized Trial of Lorecivivint, a Novel Intra-articular CLK2/DYRK1A Inhibitor and Wnt Pathway Modulator for Knee Osteoarthritis. (2021) (33)
- Altered phagocytosis by monocytes from HLA-DR2 and DR3-positive healthy adults is Fc gamma receptor specific. (1986) (33)
- Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study (2014) (32)
- Immunopathogenesis of rheumatoid arthritis. (1979) (32)
- Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys (2018) (31)
- The role of drug and disease registries in rheumatic disease epidemiology (2008) (31)
- Three siblings with scleroderma (systemic sclerosis) and two with Raynaud's phenomenon from a single kindred. (1981) (29)
- The Post-NSAID Era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis (2008) (29)
- Rheumatic fever and poststreptococcal reactive arthritis. (1995) (29)
- Marriage, social support, and adjustment to rheumatic disease. (1995) (29)
- The Pharmacokinetic Parameters of a Single Dose of a Novel Nano–formulated, Lower-Dose Oral Diclofenac (2012) (29)
- Lorecivivint, a Novel Intra-articular CLK/DYRK1A Inhibitor and Wnt Pathway Modulator for Treatment of Knee Osteoarthritis: A Phase 2 Randomized Trial. (2020) (28)
- Acute rheumatic fever and streptococci: the quintessential pathogenic trigger of autoimmunity (2014) (27)
- Cluster‐Randomized Trial of a Behavioral Intervention to Incorporate a Treat‐to‐Target Approach to Care of US Patients With Rheumatoid Arthritis (2018) (26)
- Results from a 52-week randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular wnt pathway inhibitor (SM04690) for the treatment of knee osteoarthritis (2018) (25)
- Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries (2011) (25)
- Comparative effectiveness of current treatments for rheumatoid arthritis. (2012) (24)
- Efficacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study (2015) (24)
- Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey (2020) (24)
- The identification of HL-A antigens on fresh and cultured human endothelial cells. (1975) (23)
- A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower dose oral diclofenac. (2012) (23)
- Lower-Dose Diclofenac Submicron Particle Capsules Provide Early and Sustained Acute Patient Pain Relief in a Phase 3 Study (2013) (23)
- Concomitant interferon-α therapy and tumor necrosis factor α inhibition for rheumatoid arthritis and hepatitis C (2006) (23)
- Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. (2006) (22)
- Down-titration of biologics for the treatment of rheumatoid arthritis: a systematic literature review (2017) (21)
- Trypsinization of lymphocytes for HL-A typing. (1972) (21)
- Current therapeutic agents and treatment paradigms for the management of rheumatoid arthritis. (2014) (18)
- Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study (2018) (17)
- Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors (2017) (17)
- Chronic Pain of Osteoarthritis: Considerations for Selecting an Extended-Release Opioid Analgesic (2008) (17)
- Short-term costs associated with non-medical switching in autoimmune conditions. (2019) (16)
- Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone (2015) (16)
- US rheumatologists’ beliefs and knowledge about biosimilars: a survey (2020) (14)
- The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network (2014) (14)
- Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes (2010) (13)
- Efficacy and safety from a phase 2B trial of SM04690, a novel, intra-articular, WNT pathway inhibitor for the treatment of osteoarthritis of the knee (2019) (13)
- Genetic control of the susceptibility to infection with pathogenic bacteria. (1986) (12)
- Delayed-release prednisone – a new approach to an old therapy (2013) (12)
- Geographical variations in COVID-19 perceptions and patient management: a national survey of rheumatologists (2020) (11)
- Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis (2019) (11)
- Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study. (2007) (11)
- The role of Fc gamma receptors in mononuclear phagocyte system function. (1989) (11)
- Manual of rheumatology and outpatient orthopedic disorders (2013) (10)
- Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study (2015) (10)
- THU0458 EFFICACY AND SAFETY FROM A PHASE 2B TRIAL OF SM04690, A NOVEL INTRA-ARTICULAR WNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE (2019) (10)
- Rheumatic fever: new insights into an old disease. (1993) (8)
- SAT0139 Analysis of Outcomes After Non-Medical Switching of Anti–Tumor Necrosis Factor Agents (2015) (8)
- Combination Therapy for Rheumatoid Arthritis in the Era of Biologicals (2006) (7)
- Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2). (2015) (6)
- Low-dose SoluMatrix diclofenac: a review of safety across two Phase III studies in patients with acute and osteoarthritis pain (2015) (5)
- The post-NSAID era: What to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis (2007) (5)
- The Americans with Disabilities Act of 1990--changes in existing protection and impact on the private health services provider. (1992) (4)
- The co-occurrence of acute rheumatic fever and AIDS. (1997) (4)
- Minimizing Cardiovascular Complications During the Treatment of Osteoarthritis (2011) (4)
- SAT0586 Results from a 52 week randomised, double-blind, placebo-controlled, phase 2 study of a novel, wnt pathway inhibitor (SM04690) for knee osteoarthritis treatment (2018) (4)
- AB0286 A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-To-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients (2015) (4)
- If I am not for myself, who will be for me? (2003) (4)
- Pay for performance in rheumatology: will we get the carrot or the stick? (2008) (3)
- A diagnostic approach to musculoskeletal pain. (1999) (3)
- A Phase 3 study of lower-dose diclofenac submicron particle capsules demonstrates effective pain relief in patients with osteoarthritis (2013) (3)
- Low-dose SoluMatrix diclofenac in patients with osteoarthritis pain: impact on quality of life in a controlled trial (2017) (3)
- Etiology and genetics of collagen diseases. (1992) (3)
- Diclofenac submicron particle capsules demonstrate early and sustained acute pain relief in a phase 3 study in patients following bunionectomy surgery (2013) (3)
- The arthritogenic properties of microbial antigens. Their implications in disease states. (1998) (3)
- Hydroxychloroquine and Chloroquine in COVID-19 (2020) (3)
- Erratum to: Treating rheumatoid arthritis to target: an international initiative (2011) (3)
- Scleroderma in women with silicone breast implants: comment on the article by Sánchez-Guerrero et al. (1995) (3)
- Genetics of the Hajdu-Cheney syndrome. (1987) (3)
- Risk management in endoscopic practice. (1995) (3)
- Immunological Reactions to Silicone Implants (1994) (3)
- Chronic Lyme Arthritis (2020) (2)
- Original article Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study (2014) (2)
- Increases in Certain Diseases and after Immunization * (2003) (2)
- Legal issues in allergy and clinical immunology. (1996) (2)
- Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases. (2002) (2)
- Low-dose solumatrix meloxicam demonstrates low systemic exposure and efficacy in patients with osteoarthitis pain in clinical studies (2015) (2)
- Radiographic outcomes were concordant with outcome measures in rheumatology-osteoarthritis research society international (OMERACT-OARSI) strict response: post-hoc analysis from a phase 2 study of a WNT pathway inhibitor, SM04690, for knee osteoarthritis treatment (2018) (2)
- Regulatory and legal issues in the reprocessing and reuse of hemodialyzers. A critical overview. (1988) (2)
- The developing application of antitrust laws to hospital mergers. (1994) (2)
- A Rose by Any Other Name (1967) (2)
- AB0416 Estimating the short-term costs associated with non-medical switching in rheumatic diseases (2018) (2)
- Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary (2022) (1)
- OP0136 Sex Differences in Gout Characteristics: Tailoring Care for Women and Men (2014) (1)
- AN ONLINE SURVEY AMONG US PATIENTS WITH IMMUNE-MEDIATED CONDITIONS: BELIEFS ABOUT BIOSIMILARS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2022) (1)
- FRI0052 Variations in Disease Activity and Therapeutic Management of Rheumatoid Arthritis in Different International Regions: A Comparison of Data from the Corrona International and Corrona US Registries (2014) (1)
- THU0126 Dose Titration of Biologics for The Treatment of Rheumatoid Arthritis and Ankylosing Spondylitis: A Systematic Literature Review (2016) (1)
- POS0666 TREATMENT EFFECTIVENESS OF UPADACITINIB AT 3 MONTHS IN US PATIENTS WITH RHEUMATOID ARTHRITIS FROM THE UNITED RHEUMATOLOGY NORMALIZED INTEGRATED COMMUNITY EVIDENCE (NICE[TM]) REAL-WORLD DATA (2021) (1)
- THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery (2014) (1)
- A better look at rheumatoid arthritis: Using imaging to improve patient outcomes. (2019) (1)
- Adverse presensitization: detection by utilization of B lymphoblastoid cell panels. (1979) (1)
- AB0250 REAL-WORLD OUTCOMES IN STABLE ORIGINATOR BIOLOGIC-TREATED ADULT PATIENTS WHO STAYED ON THE THERAPY VERSUS THOSE WHO SWITCHED TO BIOSIMILAR: A RETROSPECTIVE CHART REVIEW STUDY IN EUROPE (2019) (1)
- Solumatrix diclofenac safety in older patients with osteoarthritis pain (2015) (1)
- Association of HLA-DRw2 with Autoimmune (1979) (1)
- POS0436 PATIENT CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH UPADACITINIB: THE OM1 RA REGISTRY (2021) (1)
- Improving survival in inflammatory rheumatic diseases: a neglected goal? (2006) (1)
- Treating rheumatoid arthritis to target: an international initiative (2011) (1)
- Liability issues in the treatment of patients with rheumatic diseases. (1997) (1)
- OP0166 Radiographic outcomes from a randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, injectable, wnt pathway inhibitor (SM04690) in the treatment of osteoarthritis of the knee: week 26 interim analysis (2017) (1)
- Corrigendum to “Outcome measures in placebo-controlled trials of osteoarthritis: responsiveness to treatment effects in the REPORT database” [Osteoarthritis and Cartilage 19 (2011) 483–492] (2011) (1)
- Methyldopa and reticuloendothelial function. (1986) (1)
- THU0138 The Corrona International Rheumatoid Arthritis Registry: Variations in Disease Activity and Management Across Participating Regions (2013) (1)
- FRI0534 Radiographic outcomes were associated with pain and function responses: post-hoc analysis from a phase 2 study of a wnt pathway inhibitor, sm04690, for knee osteoarthritis treatment (2018) (1)
- An analysis of recent antitrust issues affecting specialty practice: is dermatology immune? (2005) (1)
- The times they are a changin'. (2013) (0)
- 313 A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF A NOVEL, PROPRIETARY, NANO-FORMULATED ORAL DICLOFENAC (2011) (0)
- SAT0552 Clinical outcomes from a randomized, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, injectable, WNT pathway inhibitor (SM04690) for the treatment of knee osteoarthritis: week 26 interim analysis (2017) (0)
- POSTSTREPTOCOCCAL REACTIVE ARTHRITIS IN CHILDREN. AUTHORS' REPLIES (1996) (0)
- S3333 An Online Survey Among US Patients with Immune-mediated Conditions: Beliefs About Biosimilars from Patients with Inflammatory Bowel Disease (2021) (0)
- AIDS. Current medical and scientific aspects. (1988) (0)
- 2008for the treatment of rheumatic diseases, Updated consensus statement on biological (2008) (0)
- CHARLES L. CHRISTIAN, MD: 1926 - 2019. (2020) (0)
- Clinical Images:Lupus erythematosus cells in the kidney and synovial fluid. (2001) (0)
- Additional file 3: Figure S1. of Sex differences in gout characteristics: tailoring care for women and men (2017) (0)
- Provider and patient knowledge gaps on biosimilars: insights from surveys. (2022) (0)
- SAT0428 Safety, Clinical and Imaging Outcomes of A Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in The Treatment of Osteoarthritis of The Knee: Exploratory Analysis of Results from A 24 Week, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study (2016) (0)
- EFFICACYAND SAFETYFROMAPHASE 2B TRIALOF SM04690, A NOVEL, INTRA-ARTICULARWNT PATHWAY INHIBITOR FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE (2021) (0)
- 115 – Poststreptococcal Arthritis and Rheumatic Fever (2013) (0)
- Biosimilars for immune-mediated inflammatory diseases: a managed care perspective. (2022) (0)
- Medical Legal Issues with Biologic Agents in the Treatment of Psoriasis (2018) (0)
- THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies (2014) (0)
- P E R I P H E R A L B L O O D Ia -POSITIVE T CELLS Increases in Certain Diseases and after Immunization* (2003) (0)
- The Americans with Disabilities Act of 1990. Changes in existing protection and impact on the private health services provider. (1992) (0)
- Rheumatic fever. (1989) (0)
- POS0686 EFFECTIVENESS OF UPADACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: ANALYSIS OF 6-MONTH REAL-WORLD DATA FROM THE UNITED RHEUMATOLOGY NORMALIZED INTEGRATED COMMUNITY EVIDENCE (UR-NICETM) DATABASE (2022) (0)
- NEW AGENTS FOR RHEUMATOID ARTHRITIS (2013) (0)
- Yearbook of health care management 1991 (1991) (0)
- HIGHLIGHTS FROM AN INTERNATIONAL CONFERENCE PART II: Focus on Psoriatic Arthritis and Ankylosing Spondylitis (2014) (0)
- Rheumatology today : pathways to progress : proceedings of a symposium (1997) (0)
- SAT0640-HPR Understanding The Importance of A Patient's Role in The Management of RA: Physician- and Patient-Based Survey Results Developed by The RA Narrative Advisory Panel (2016) (0)
- (380) A novel application of the Medication Event Monitoring System (MEMS) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain. (2016) (0)
- Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidence. (2022) (0)
- Immunological aspects of cardiac disease (2009) (0)
- (402) Indomethacin submicron particle capsules: reduced opioid rescue medication usage in a phase 3 study in patients with acute pain after elective surgery (2014) (0)
- Proceedings of the 2013 Rheumatology Winter Clinical Symposia. (2013) (0)
- Medicare fraud regulations and the implications for joint ventures: are we working at cross purposes? (1995) (0)
- Breast implants and connective-tissue diseases. (1994) (0)
- The role of professional education in improving quality of life. (1992) (0)
- Immunopathology. edited by felix milagrom and boris albini. basel, switzerland, s. karger, 1978. 350 pages. illustrated. $97.25. (1980) (0)
- Low-dose SoluMatrix meloxicam results in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis (2016) (0)
- In Memoriam: Charles L. Christian, MD, 1926–2019 (2019) (0)
- AB0460 Long-term drug survival of etanercept vs other tnf inhibitor therapies in patients with rheumatoid arthritis (2018) (0)
- Cardiac Disease, Autoimmune (1998) (0)
- SAT0134 Prevalence of Cardiovascular Risk Factors and Cardiovascular Disease in Rheumatoid Arthritis Patients across International Regions: A Comparison of the Corrona International and Corrona US Registries (2014) (0)
- THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain (2014) (0)
- An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars. (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Allan Gibofsky?
Allan Gibofsky is affiliated with the following schools:
